These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 22283898)
21. Implementation of the INNO-LiPA Rif. TB® line-probe assay in rapid detection of multidrug-resistant tuberculosis in Latvia. Skenders GK; Holtz TH; Riekstina V; Leimane V Int J Tuberc Lung Dis; 2011 Nov; 15(11):1546-52, i. PubMed ID: 22008771 [TBL] [Abstract][Full Text] [Related]
22. Experiences of a community-based tuberculosis treatment programme in Namibia: a comparative cohort study. Zvavamwe Z; Ehlers VJ Int J Nurs Stud; 2009 Mar; 46(3):302-9. PubMed ID: 18995854 [TBL] [Abstract][Full Text] [Related]
23. Management of multi drug resistance tuberculosis in the field: Tuberculosis Research Centre experience. Thomas A; Ramachandran R; Rehaman F; Jaggarajamma K; Santha T; Selvakumar N; Krishnan N; Mohan NS; Sundaram V; Wares F; Narayanan PR Indian J Tuberc; 2007 Jul; 54(3):117-24. PubMed ID: 17886699 [TBL] [Abstract][Full Text] [Related]
24. Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multidrug-resistant tuberculosis in New York City. Mannheimer SB; Sepkowitz KA; Stoeckle M; Friedman CR; Hafner A; Riley LW Int J Tuberc Lung Dis; 1997 Aug; 1(4):319-25. PubMed ID: 9432387 [TBL] [Abstract][Full Text] [Related]
25. Factors associated with declining numbers of chronic tuberculosis excretors in Japan. Hoshino H; Uchimura K; Kato S Int J Tuberc Lung Dis; 2011 Feb; 15(2):169-73, i. PubMed ID: 21219676 [TBL] [Abstract][Full Text] [Related]
26. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154 [TBL] [Abstract][Full Text] [Related]
27. Surgical treatment for multidrug-resistant and extensive drug-resistant tuberculosis. Kang MW; Kim HK; Choi YS; Kim K; Shim YM; Koh WJ; Kim J Ann Thorac Surg; 2010 May; 89(5):1597-602. PubMed ID: 20417785 [TBL] [Abstract][Full Text] [Related]
28. Representative drug susceptibility patterns for guiding design of re-treatment regimens for multidrug-resistant tuberculosis in Iran. Tabarsi P; Nooraki A; Mirsaeidi M; Amiri M; Baghaei P; Farnia P; Kazempour M; Heidarnazhad H; Alipanah N; Mansouri D; Masjedi MR Respirology; 2008 Jan; 13(1):108-11. PubMed ID: 18197919 [TBL] [Abstract][Full Text] [Related]
29. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia. Riekstina V; Leimane V; Holtz TH; Leimans J; Wells CD Int J Tuberc Lung Dis; 2007 May; 11(5):585-7. PubMed ID: 17439686 [TBL] [Abstract][Full Text] [Related]
30. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects. Yew WW Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001 [TBL] [Abstract][Full Text] [Related]
31. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Chavez Pachas AM; Blank R; Smith Fawzi MC; Bayona J; Becerra MC; Mitnick CD Int J Tuberc Lung Dis; 2004 Jan; 8(1):52-8. PubMed ID: 14974746 [TBL] [Abstract][Full Text] [Related]
32. The treatment results of patients with multidrug resistant tuberculosis and factors affecting treatment outcome. Karagöz T; Yazicioğlu Moçin O; Pazarli P; Senol T; Yetiş Duman D; Duman G; Saltürk C; Unal O; Halezeroğlu S Tuberk Toraks; 2009; 57(4):383-92. PubMed ID: 20037853 [TBL] [Abstract][Full Text] [Related]
33. Responding to the multidrug-resistant tuberculosis crisis: mainstreaming programmatic management to the Philippine National Tuberculosis Programme. Quelapio MI; Mira NR; Orillaza-Chi RB; Belen V; Muñez N; Belchez R; Egos GE; Evangelista M; Vianzon R; Tupasi TE Int J Tuberc Lung Dis; 2010 Jun; 14(6):751-7. PubMed ID: 20487615 [TBL] [Abstract][Full Text] [Related]
34. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Yoshiyama T; Yanai H; Rhiengtong D; Palittapongarnpim P; Nampaisan O; Supawitkul S; Uthaivorawit W; Mori T Int J Tuberc Lung Dis; 2004 Jan; 8(1):31-8. PubMed ID: 14974743 [TBL] [Abstract][Full Text] [Related]
35. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Shean KP; Willcox PA; Siwendu SN; Laserson KF; Gross L; Kammerer S; Wells CD; Holtz TH Int J Tuberc Lung Dis; 2008 Oct; 12(10):1182-9. PubMed ID: 18812049 [TBL] [Abstract][Full Text] [Related]
36. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Pablos-Mendez A; Gowda DK; Frieden TR Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008 [TBL] [Abstract][Full Text] [Related]
37. Qualitative study of perceived causes of tuberculosis treatment default among health care workers in Morocco. Kizub D; Ghali I; Sabouni R; Bourkadi JE; Bennani K; El Aouad R; Dooley KE Int J Tuberc Lung Dis; 2012 Sep; 16(9):1214-20. PubMed ID: 22793783 [TBL] [Abstract][Full Text] [Related]
38. The effects of increasing incentives on adherence to tuberculosis directly observed therapy. Davidson H; Schluger NW; Feldman PH; Valentine DP; Telzak EE; Laufer FN Int J Tuberc Lung Dis; 2000 Sep; 4(9):860-5. PubMed ID: 10985655 [TBL] [Abstract][Full Text] [Related]
40. Can guardians supervise TB treatment as well as health workers? A study on adherence during the intensive phase. Manders AJ; Banerjee A; van den Borne HW; Harries AD; Kok GJ; Salaniponi FM Int J Tuberc Lung Dis; 2001 Sep; 5(9):838-42. PubMed ID: 11573895 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]